{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:35:46Z","timestamp":1794580546307,"version":"4.9.1"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260846"],"award-info":[{"award-number":["82260846"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Program Foundation of Qinghai Province","award":["2023-ZJ-754"],"award-info":[{"award-number":["2023-ZJ-754"]}]},{"name":"Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["JYY2023-14"],"award-info":[{"award-number":["JYY2023-14"]}]},{"name":"Beijing Traditional Chinese Medicine Science and Technology Development Fund Project","award":["BJZYYB-2025-24"],"award-info":[{"award-number":["BJZYYB-2025-24"]}]},{"name":"Research Project of Inner Mongolia Medical University Affiliated Hospital","award":["2023NYFYLHZD007"],"award-info":[{"award-number":["2023NYFYLHZD007"]}]},{"name":"Beijing Municipal Administration of Hospital Incubating Program","award":["PX2023059"],"award-info":[{"award-number":["PX2023059"]}]},{"name":"The Capability Program of Beijing Tuberculosis & Thoracic Tumor Research Institute","award":["NLTS2024-16"],"award-info":[{"award-number":["NLTS2024-16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04417-y","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:28:29Z","timestamp":1776252509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intranasal administration in modulating depressive-like behavior and reconstructing treatment paradigms through neuroinflammation and neurotrophic pathways"],"prefix":"10.1186","volume":"24","author":[{"given":"Juan","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"1","key":"4417_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00481-w","volume":"14","author":"I Drath","year":"2025","unstructured":"Drath I, Richter F, Feja M. Nose-to-brain drug delivery: from bench to bedside. Transl Neurodegener. 2025;14(1):23. https:\/\/doi.org\/10.1186\/s40035-025-00481-w.","journal-title":"Transl Neurodegener"},{"issue":"7","key":"4417_CR2","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.5c00297","volume":"22","author":"S Rezaee","year":"2025","unstructured":"Rezaee S, Al-Majdoub ZM, Galetin A, Rostami-Hodjegan A, Ogungbenro K. Challenges and opportunities for incorporating physiological information into pharmacokinetic models of intranasal drug delivery to the brain: a review of the current status and future trajectories. Mol Pharm. 2025;22(7):3563\u201377. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00297.","journal-title":"Mol Pharm"},{"issue":"5","key":"4417_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050615","volume":"18","author":"TT Nguyen","year":"2025","unstructured":"Nguyen TT, Duong VA. Advancements in nanocarrier systems for nose-to-brain drug delivery. Pharmaceuticals (Basel). 2025;18(5):615. https:\/\/doi.org\/10.3390\/ph18050615.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"4417_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091180","volume":"17","author":"R Safarov","year":"2024","unstructured":"Safarov R, Fedotova O, Uvarova A, Gordienko M, Menshutina N. Review of intranasal active pharmaceutical ingredient delivery systems. Pharmaceuticals (Basel). 2024;17(9):1180. https:\/\/doi.org\/10.3390\/ph17091180.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4417_CR5","doi-asserted-by":"publisher","unstructured":"Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9(3):S5. https:\/\/doi.org\/10.1186\/1471-2202-9-S3-S5.","DOI":"10.1186\/1471-2202-9-S3-S5"},{"key":"4417_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejps.2014.04.019","volume":"60","author":"A Serralheiro","year":"2014","unstructured":"Serralheiro A, Alves G, Fortuna A, Falc\u00e3o A. Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. Eur J Pharm Sci. 2014;60:32\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2014.04.019.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"4417_CR7","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.drudis.2019.06.001","volume":"24","author":"C Vitorino","year":"2019","unstructured":"Vitorino C, Silva S, Bicker J, Falc\u00e3o A, Fortuna A. Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. Drug Discov Today. 2019;24(9):1911\u201323. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.001.","journal-title":"Drug Discov Today"},{"key":"4417_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejpb.2023.12.002","volume":"194","author":"S Silva","year":"2024","unstructured":"Silva S, Fonseca C, Bicker J, Falc\u00e3o A, Fortuna A. Intranasal administration of sertraline ensures sustained brain delivery and antidepressant effect in a mouse model of depression. Eur J Pharm Biopharm. 2024;194:118\u201330. https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.002.","journal-title":"Eur J Pharm Biopharm"},{"issue":"10128","key":"4417_CR9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7.","journal-title":"Lancet"},{"issue":"1","key":"4417_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-025-01219-6","volume":"20","author":"KN Tran","year":"2025","unstructured":"Tran KN, Munni YA, Nguyen LTH, et al. Novel intranasal delivery of sihosogansan demonstrates rapid antidepressant activity via GABAergic and BDNF\/TrkB pathways: identification of potential bioactive quality markers. Chin Med. 2025;20(1):162. https:\/\/doi.org\/10.1186\/s13020-025-01219-6.","journal-title":"Chin Med"},{"key":"4417_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","volume":"270","author":"PC Pires","year":"2018","unstructured":"Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release. 2018;270:89\u2013100. https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.047.","journal-title":"J Control Release"},{"key":"4417_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151 F, Bors LA, Farkas D, Bajza \u00c1, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155\u201370. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.10.009.","journal-title":"Brain Res Bull"},{"issue":"1","key":"4417_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety concerns with Esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom. 2021;90(1):41\u20138. https:\/\/doi.org\/10.1159\/000510703.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"4417_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42\u201362. https:\/\/doi.org\/10.1007\/s13346-012-0108-9.","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"4417_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"LA Keller","year":"2022","unstructured":"Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735\u201357. https:\/\/doi.org\/10.1007\/s13346-020-00891-5.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"4417_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","volume":"161","author":"L Illum","year":"2012","unstructured":"Illum L. Nasal drug delivery - recent developments and future prospects. J Control Release. 2012;161(2):254\u201363. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.024.","journal-title":"J Control Release"},{"issue":"5","key":"4417_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383\u201399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251.","journal-title":"Am J Psychiatry"},{"key":"4417_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jpsychires.2024.11.010","volume":"180","author":"S Oraee","year":"2024","unstructured":"Oraee S, Alinejadfard M, Golsorkh H, et al. Intranasal esketamine for patients with major depressive disorder: a systematic review and meta-analysis. J Psychiatr Res. 2024;180:371\u20139. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.11.010.","journal-title":"J Psychiatr Res"},{"key":"4417_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2026.121257","volume":"401","author":"C de Oliveira Lapa","year":"2026","unstructured":"de Oliveira Lapa C, Viola T, Delfino R, et al. Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: evidence from real-world studies. J Affect Disord. 2026;401:121257. https:\/\/doi.org\/10.1016\/j.jad.2026.121257.","journal-title":"J Affect Disord"},{"key":"4417_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-026-07980-8","author":"BT Baune","year":"2026","unstructured":"Baune BT, Rosemann K, Hefter D, Tonkul M, Kavakbasi E. Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response. BMC Psychiatry. 2026. https:\/\/doi.org\/10.1186\/s12888-026-07980-8.","journal-title":"BMC Psychiatry"},{"key":"4417_CR21","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.2147\/IJN.S525759","volume":"20","author":"M Patel","year":"2025","unstructured":"Patel M, Minglani VV, Vaddadi H, et al. Advancements in Nanotherapeutics for the Treatment of Depression via Intranasal Pathway: A Review. Int J Nanomed. 2025;20:7323\u201342. https:\/\/doi.org\/10.2147\/IJN.S525759.","journal-title":"Int J Nanomed"},{"issue":"14","key":"4417_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","volume":"389","author":"A Reif","year":"2023","unstructured":"Reif A, Bitter I, Buyze J, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389(14):1298\u2013309. https:\/\/doi.org\/10.1056\/NEJMoa2304145.","journal-title":"N Engl J Med"},{"issue":"5","key":"4417_CR23","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00406-025-02066-0","volume":"275","author":"MM Zhao","year":"2025","unstructured":"Zhao MM, Yang JJ, Hashimoto K. Ketamine and its enantiomers in treatment-resistant depression: promise, pitfalls, and personalized psychiatry. Eur Arch Psychiatry Clin Neurosci. 2025;275(5):1267\u20139. https:\/\/doi.org\/10.1007\/s00406-025-02066-0.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"4417_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060775","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Zang R, Qiu Y, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: challenges, advances, and future research directions. Pharmaceutics. 2025;17(6):775. https:\/\/doi.org\/10.3390\/pharmaceutics17060775.","journal-title":"Pharmaceutics"},{"issue":"11","key":"4417_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70198","volume":"14","author":"K Jin","year":"2025","unstructured":"Jin K, Wang R, Chen B, et al. Nose-to-Brain delivery of Chlorella vulgaris extracellular vesicles for antidepressant effects. J Extracell Vesicles. 2025;14(11):e70198. https:\/\/doi.org\/10.1002\/jev2.70198.","journal-title":"J Extracell Vesicles"},{"issue":"7","key":"4417_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071985","volume":"15","author":"D Mohanty","year":"2023","unstructured":"Mohanty D, Alsaidan OA, Zafar A, et al. Development of Atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: optimization, in vitro, and preclinical evaluation. Pharmaceutics. 2023;15(7):1985. https:\/\/doi.org\/10.3390\/pharmaceutics15071985.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4417_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/0122117385301604240226111533","volume":"13","author":"MA Tamer","year":"2025","unstructured":"Tamer MA, Kassab HJ. Optimizing intranasal Amisulpride loaded nanostructured lipid carriers: formulation, development, and characterization parameters. Pharm Nanotechnol. 2025;13(2):287\u2013302. https:\/\/doi.org\/10.2174\/0122117385301604240226111533.","journal-title":"Pharm Nanotechnol"},{"issue":"2","key":"4417_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1745-7254.2007.00486.x","volume":"28","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Yue P, Tao T, Chen QH. Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol Sin. 2007;28(2):273\u20138. https:\/\/doi.org\/10.1111\/j.1745-7254.2007.00486.x.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"4417_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.146761","volume":"322","author":"H Yang","year":"2025","unstructured":"Yang H, Liu R, Huang J, et al. Nose-to-brain delivery of biomineralized silk fibroin nanoparticles synergistically extinguish neuroinflammation for efficient depressive-like symptoms alleviation. Int J Biol Macromol. 2025;322(2):146761. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146761.","journal-title":"Int J Biol Macromol"},{"key":"4417_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121050","volume":"607","author":"D Gadhave","year":"2021","unstructured":"Gadhave D, Tupe S, Tagalpallewar A, Gorain B, Choudhury H, Kokare C. Nose-to-brain delivery of amisulpride-loaded lipid-based poloxamer-gellan gum nanoemulgel: in vitro and in vivo pharmacological studies. Int J Pharm. 2021;607:121050. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121050.","journal-title":"Int J Pharm"},{"issue":"6","key":"4417_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.cell.2025.01.017","volume":"188","author":"H Shen","year":"2025","unstructured":"Shen H, Aggarwal N, Cui B, et al. Engineered commensals for targeted nose-to-brain drug delivery. Cell. 2025;188(6):1545-1562.e16. https:\/\/doi.org\/10.1016\/j.cell.2025.01.017.","journal-title":"Cell"},{"issue":"3","key":"4417_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/jpet.119.258152","volume":"370","author":"Z Wang","year":"2019","unstructured":"Wang Z, Xiong G, Tsang WC, Sch\u00e4tzlein AG, Uchegbu IF. Nose-to-Brain delivery. J Pharmacol Exp Ther. 2019;370(3):593\u2013601. https:\/\/doi.org\/10.1124\/jpet.119.258152.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4417_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/10717544.2019.1650848","volume":"26","author":"A Ali","year":"2019","unstructured":"Ali A, Wahlgren M, Rembratt-Svensson B, et al. Dehydration affects drug transport over nasal mucosa. Drug Deliv. 2019;26(1):831\u201340. https:\/\/doi.org\/10.1080\/10717544.2019.1650848.","journal-title":"Drug Deliv"},{"key":"4417_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125584","volume":"676","author":"S Wei","year":"2025","unstructured":"Wei S, Zhai Z, Kong X, et al. The review of nasal drug delivery system: the strategies to enhance the efficiency of intranasal drug delivery by improving drug absorption. Int J Pharm. 2025;676:125584. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125584.","journal-title":"Int J Pharm"},{"issue":"2","key":"4417_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1956","volume":"16","author":"K Xu","year":"2024","unstructured":"Xu K, Duan S, Wang W, et al. Nose-to-brain delivery of nanotherapeutics: transport mechanisms and applications. WIREs Nanomed Nanobiotechnol. 2024;16(2):e1956. https:\/\/doi.org\/10.1002\/wnan.1956.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"4417_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/IJN.S481917","volume":"20","author":"C Serri","year":"2025","unstructured":"Serri C, Piccioni M, Guarino V, et al. Hyaluronic Acid-Based Hybrid Nanoparticles as Promising Carriers for the Intranasal Administration of Dimethyl Fumarate. Int J Nanomed. 2025;20:71\u201389. https:\/\/doi.org\/10.2147\/IJN.S481917.","journal-title":"Int J Nanomed"},{"issue":"8","key":"4417_CR37","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1021\/acs.molpharmaceut.1c00366","volume":"18","author":"AR Clementino","year":"2021","unstructured":"Clementino AR, Pellegrini G, Banella S, et al. Structure and fate of nanoparticles designed for the nasal delivery of poorly soluble drugs. Mol Pharm. 2021;18(8):3132\u201346. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00366.","journal-title":"Mol Pharm"},{"key":"4417_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.150797","volume":"347","author":"SS Das","year":"2026","unstructured":"Das SS, Kumar A, Joshi B, Alipour S, Dehshahri A. Molecular insights, challenges and progressions of polysaccharide and protein-based biopolymeric carriers for intranasal drug delivery: a review. Int J Biol Macromol. 2026;347:150797. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150797.","journal-title":"Int J Biol Macromol"},{"key":"4417_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.msec.2015.11.028","volume":"59","author":"C Karavasili","year":"2016","unstructured":"Karavasili C, Bouropoulos N, Sygellou L, Amanatiadou EP, Vizirianakis IS, Fatouros DG. PLGA\/DPPC\/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment. Mater Sci Eng C Mater Biol Appl. 2016;59:1053\u201362. https:\/\/doi.org\/10.1016\/j.msec.2015.11.028.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"4417_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2019.02.012","volume":"560","author":"S Yu","year":"2019","unstructured":"Yu S, Xu X, Feng J, Liu M, Hu K. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. Int J Pharm. 2019;560:282\u201393. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.02.012.","journal-title":"Int J Pharm"},{"key":"4417_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.actbio.2019.08.022","volume":"97","author":"TW Huang","year":"2019","unstructured":"Huang TW, Li ST, Wang YH, Young TH. Regulation of chitosan-mediated differentiation of human olfactory receptor neurons by insulin-like growth factor binding protein-2. Acta Biomater. 2019;97:399\u2013408. https:\/\/doi.org\/10.1016\/j.actbio.2019.08.022.","journal-title":"Acta Biomater"},{"key":"4417_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03528-2","volume":"23","author":"N Sanadgol","year":"2025","unstructured":"Sanadgol N, Abedi M, Hashemzaei M, et al. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. J Nanobiotechnol. 2025;23:453. https:\/\/doi.org\/10.1186\/s12951-025-03528-2.","journal-title":"J Nanobiotechnol"},{"key":"4417_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.865682","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Zhao X, Zhong Y, Shen J, An W. Biomimetic exosomes: a new generation of drug delivery system. Front Bioeng Biotechnol. 2022;10:865682. https:\/\/doi.org\/10.3389\/fbioe.2022.865682.","journal-title":"Front Bioeng Biotechnol"},{"key":"4417_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00631-2","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen L, Hong W, Ren W, et al. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Sig Transduct Target Ther. 2021;6:225. https:\/\/doi.org\/10.1038\/s41392-021-00631-2.","journal-title":"Sig Transduct Target Ther"},{"issue":"14","key":"4417_CR45","doi-asserted-by":"publisher","first-page":"10142","DOI":"10.1021\/acsnano.3c13088","volume":"18","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhan M, Karpus A, et al. Brain delivery of biomimetic phosphorus dendrimer\/antibody nanocomplexes for enhanced glioma immunotherapy via immune modulation of T cells and natural killer cells. ACS Nano. 2024;18(14):10142\u201355. https:\/\/doi.org\/10.1021\/acsnano.3c13088.","journal-title":"ACS Nano"},{"key":"4417_CR46","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jconrel.2024.10.058","volume":"376","author":"H Tian","year":"2024","unstructured":"Tian H, Yao J, Ba Q, et al. Cerebral biomimetic nano-drug delivery systems: A frontier strategy for immunotherapy. J Control Release. 2024;376:1039\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.058.","journal-title":"J Control Release"},{"key":"4417_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","volume":"344","author":"T Kurano","year":"2022","unstructured":"Kurano T, Kanazawa T, Ooba A, et al. Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties. J Control Release. 2022;344:225\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.017.","journal-title":"J Control Release"},{"issue":"4","key":"4417_CR48","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11095-022-03222-0","volume":"39","author":"T Yuan","year":"2022","unstructured":"Yuan T, Gao L, Zhan W, Dini D. Effect of particle size and surface charge on nanoparticles diffusion in the brain white matter. Pharm Res. 2022;39(4):767\u201381. https:\/\/doi.org\/10.1007\/s11095-022-03222-0.","journal-title":"Pharm Res"},{"key":"4417_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105693","volume":"96","author":"MM Ali","year":"2024","unstructured":"Ali MM, Shoukri RA, Yousry C. Effect of particle size versus surface charge on the brain targeting behavior of elastic nanovesicles: in-vitro characterization, comparison between I-optimal and D-optimal statistical optimization and in-vivo pharmacokinetic evaluation. J Drug Deliv Sci Technol. 2024;96:105693. https:\/\/doi.org\/10.1016\/j.jddst.2024.105693.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"4417_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1381612829666221223101753","volume":"29","author":"J Kanoujia","year":"2023","unstructured":"Kanoujia J, Kishore A, Parashar P. Progress in polymeric micelles as viable wagons for brain targeting. Curr Pharm Des. 2023;29(2):116\u201325. https:\/\/doi.org\/10.2174\/1381612829666221223101753.","journal-title":"Curr Pharm Des"},{"key":"4417_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109960","volume":"361","author":"J Kaur","year":"2022","unstructured":"Kaur J, Gulati M, Kapoor B, et al. Advances in designing of polymeric micelles for biomedical application in brain related diseases. Chem Biol Interact. 2022;361:109960. https:\/\/doi.org\/10.1016\/j.cbi.2022.109960.","journal-title":"Chem Biol Interact"},{"key":"4417_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2024.100225","volume":"21","author":"BA Makalew","year":"2025","unstructured":"Makalew BA, Abrori SA. Material informatics-driven insights into brain cancer nanocarriers: a bibliometric comparison of PLGA vs. liposomes. Open Nano. 2025;21:100225. https:\/\/doi.org\/10.1016\/j.onano.2024.100225.","journal-title":"Open Nano"},{"issue":"1","key":"4417_CR53","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","volume":"28","author":"Y Su","year":"2021","unstructured":"Su Y, Zhang B, Sun R, et al. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 2021;28(1):1397\u2013418. https:\/\/doi.org\/10.1080\/10717544.2021.1938756.","journal-title":"Drug Deliv"},{"issue":"5","key":"4417_CR54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s13346-019-00622-5","volume":"9","author":"K Nigam","year":"2019","unstructured":"Nigam K, Kaur A, Tyagi A, et al. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv Transl Res. 2019;9(5):879\u201390. https:\/\/doi.org\/10.1007\/s13346-019-00622-5.","journal-title":"Drug Deliv Transl Res"},{"issue":"31","key":"4417_CR55","doi-asserted-by":"publisher","first-page":"17947","DOI":"10.1039\/d5nr00870k","volume":"17","author":"M Bolon","year":"2025","unstructured":"Bolon M, Fieux M, Monge C, Richard S. Polymeric nanoparticles for efficient nose-to-brain delivery. Nanoscale. 2025;17(31):17947\u201379. https:\/\/doi.org\/10.1039\/d5nr00870k.","journal-title":"Nanoscale"},{"key":"4417_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.107347","volume":"113","author":"A Mehmood","year":"2025","unstructured":"Mehmood A, Javaid S, Rehman SU, Ahmed N, Kanwal S, Baig MM. Exploring drug administration routes using chitosan-based polymeric nanoparticles: a comprehensive review. J Drug Deliv Sci Technol. 2025;113:107347. https:\/\/doi.org\/10.1016\/j.jddst.2025.107347.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4417_CR57","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijbiomac.2019.02.005","volume":"129","author":"E Vieri Piazzini","year":"2019","unstructured":"Vieri Piazzini E, Landucci MDA, Fasiolo LT, Cinci L, Colombo G, Pellegrini-Giampietro DE. Anna Rita Bilia, Cristina Luceri, Maria Camilla Bergonzi. Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery. Int J Biol Macromol. 2019;129:267\u201380. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.02.005.","journal-title":"Int J Biol Macromol"},{"key":"4417_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.732954","volume":"12","author":"LM Spindler","year":"2021","unstructured":"Spindler LM, Feuerhake A, Ladel S, et al. Nano-in-micro-particles consisting of PLGA nanoparticles embedded in chitosan microparticles via spray-drying enhances their uptake in the olfactory mucosa. Front Pharmacol. 2021;12:732954. https:\/\/doi.org\/10.3389\/fphar.2021.732954.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4417_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2279-z","volume":"35","author":"B Shah","year":"2018","unstructured":"Shah B, Khunt D, Misra M, Padh H. Formulation and in-vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting. Pharm Res. 2018;35(1):8. https:\/\/doi.org\/10.1007\/s11095-017-2279-z.","journal-title":"Pharm Res"},{"issue":"8","key":"4417_CR60","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.5b00088","volume":"12","author":"A Mistry","year":"2015","unstructured":"Mistry A, Stolnik S, Illum L. Nose-to-brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol Pharm. 2015;12(8):2755\u201366. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00088.","journal-title":"Mol Pharm"},{"issue":"4","key":"4417_CR61","doi-asserted-by":"publisher","DOI":"10.1208\/pt020420","volume":"2","author":"ST Lim","year":"2001","unstructured":"Lim ST, Forbes B, Martin GP, Brown MB. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate. AAPS PharmSciTech. 2001;2(4):20. https:\/\/doi.org\/10.1208\/pt020420.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"4417_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020084","volume":"11","author":"MC Bonferoni","year":"2019","unstructured":"Bonferoni MC, Rossi S, Sandri G, et al. Nanoemulsions for \u201cnose-to-brain\u201d drug delivery. Pharmaceutics. 2019;11(2):84. https:\/\/doi.org\/10.3390\/pharmaceutics11020084.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4417_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020138","volume":"12","author":"P Giunchedi","year":"2020","unstructured":"Giunchedi P, Gavini E, Bonferoni MC. Nose-to-brain delivery. Pharmaceutics. 2020;12(2):138. https:\/\/doi.org\/10.3390\/pharmaceutics12020138.","journal-title":"Pharmaceutics"},{"issue":"12","key":"4417_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121230","volume":"12","author":"S Bahadur","year":"2020","unstructured":"Bahadur S, Pardhi DM, Rautio J, Rosenholm JM, Pathak K. Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders. Pharmaceutics. 2020;12(12):1230. https:\/\/doi.org\/10.3390\/pharmaceutics12121230.","journal-title":"Pharmaceutics"},{"key":"4417_CR65","doi-asserted-by":"publisher","first-page":"1748824","DOI":"10.3389\/fphar.2025.1748824","volume":"16","author":"K Cheng","year":"2026","unstructured":"Cheng K, Zhao H, He K, et al. Progress, critical challenges, and translational prospects of intranasal administration of botanical essential oils for the treatment of depression. Front Pharmacol. 2026;16:1748824. https:\/\/doi.org\/10.3389\/fphar.2025.1748824.","journal-title":"Front Pharmacol"},{"key":"4417_CR66","doi-asserted-by":"publisher","first-page":"125692","DOI":"10.1016\/j.ijpharm.2025.125692","volume":"678","author":"MD Cayero-Otero","year":"2025","unstructured":"Cayero-Otero MD, Perez-Caballero L, Suarez-Pereira I, et al. Venlafaxine-PLGA nanoparticles provide a fast onset of action in an animal model of depression via nose-to-brain. Int J Pharm. 2025;678:125692. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125692.","journal-title":"Int J Pharm"},{"issue":"4","key":"4417_CR67","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12031-025-02411-x","volume":"75","author":"AR Tekade","year":"2025","unstructured":"Tekade AR, Kadam PV, Aswar MK, Gaikwad AB, Shinde RB, Kharade SS. Fluoxetine HCl-loaded nanostructured lipid carriers for nose-to-brain delivery: optimization and synergistic role of saffron oil. J Mol Neurosci. 2025;75(4):126. https:\/\/doi.org\/10.1007\/s12031-025-02411-x.","journal-title":"J Mol Neurosci"},{"issue":"6","key":"4417_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70213","volume":"6","author":"Q Y","year":"2025","unstructured":"Y Q, S H, L P, et al. The nasal-brain drug delivery route: mechanisms and applications to central nervous system diseases. MedComm (2020). 2025;6(6):e70213. https:\/\/doi.org\/10.1002\/mco2.70213.","journal-title":"MedComm (2020)"},{"issue":"11","key":"4417_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11110598","volume":"11","author":"JJ Lochhead","year":"2019","unstructured":"Lochhead JJ, Davis TP. Perivascular and perineural pathways involved in brain delivery and distribution of drugs after intranasal administration. Pharmaceutics. 2019;11(11):598. https:\/\/doi.org\/10.3390\/pharmaceutics11110598.","journal-title":"Pharmaceutics"},{"key":"4417_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2025.149644","volume":"1858","author":"MT Lin","year":"2025","unstructured":"Lin MT, Chan TY, Liao WH, Wu CH, Young TH, Chen WS. Intranasal drug delivery dynamics: extracellular and intracellular pathways revealed by fluoro-gold tracer in a mouse model. Brain Res. 2025;1858:149644. https:\/\/doi.org\/10.1016\/j.brainres.2025.149644.","journal-title":"Brain Res"},{"issue":"6","key":"4417_CR71","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jsps.2016.12.003","volume":"25","author":"GF Tong","year":"2017","unstructured":"Tong GF, Qin N, Sun LW. Development and evaluation of desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm J. 2017;25(6):844\u201351. https:\/\/doi.org\/10.1016\/j.jsps.2016.12.003.","journal-title":"Saudi Pharm J"},{"key":"4417_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119550","volume":"586","author":"D Xu","year":"2020","unstructured":"Xu D, Lu YR, Kou N, Hu MJ, Wang QS, Cui YL. Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity. Int J Pharm. 2020;586:119550. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119550.","journal-title":"Int J Pharm"},{"issue":"11","key":"4417_CR73","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1021\/acs.molpharmaceut.5c00863","volume":"22","author":"TK Ponduri","year":"2025","unstructured":"Ponduri TK, Guntupalli C, Jeganathan B, Malothu N, Kowtharapu S. Transferrin-conjugated chitosan nanoparticles for direct nose-to-brain delivery of ziprasidone: pharmacokinetic and pharmacodynamic evaluation. Mol Pharm. 2025;22(11):6941\u201355. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00863.","journal-title":"Mol Pharm"},{"key":"4417_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152797","volume":"788","author":"KAB Pereira","year":"2025","unstructured":"Pereira KAB, Premazzi MCA, de Lima Gon\u00e7alves V, et al. Optimization of cationic functionalized nanoparticles for brain targeting: in vivo evaluation. Biochem Biophys Res Commun. 2025;788:152797. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152797.","journal-title":"Biochem Biophys Res Commun"},{"key":"4417_CR75","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jconrel.2022.11.051","volume":"353","author":"X Gao","year":"2023","unstructured":"Gao X, Xiong Y, Chen H, et al. Mucus adhesion vs. mucus penetration? Screening nanomaterials for nasal inhalation by MD simulation. J Control Release. 2023;353:366\u201379. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.051.","journal-title":"J Control Release"},{"issue":"4","key":"4417_CR76","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/1567201812666150507120124","volume":"13","author":"D Sharma","year":"2016","unstructured":"Sharma D, Sharma RK, Bhatnagar A, et al. Nose to brain delivery of midazolam loaded PLGA nanoparticles: in vitro and in vivo investigations. Curr Drug Deliv. 2016;13(4):557\u201364. https:\/\/doi.org\/10.2174\/1567201812666150507120124.","journal-title":"Curr Drug Deliv"},{"key":"4417_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2026.111651","volume":"145","author":"CH Miller","year":"2026","unstructured":"Miller CH, Hickman A, Baten C, et al. Ketamine pharmacotherapy for major depressive disorder: a narrative review. Prog Neuropsychopharmacol Biol Psychiatry. 2026;145:111651. https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111651.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4417_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109357","volume":"225","author":"TML Nguyen","year":"2023","unstructured":"Nguyen TML, Defaix C, Mendez-David I, et al. Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory\/inhibitory synaptic activity. Neuropharmacology. 2023;225:109357. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109357.","journal-title":"Neuropharmacology"},{"key":"4417_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109769","volume":"242","author":"R Liu","year":"2024","unstructured":"Liu R, Sun D, Xing X, et al. Intranasal oxytocin alleviates comorbid depressive symptoms in neuropathic pain via elevating hippocampal BDNF production in both female and male mice. Neuropharmacology. 2024;242:109769. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109769.","journal-title":"Neuropharmacology"},{"key":"4417_CR80","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/NDT.S227598","volume":"16","author":"C Chen","year":"2020","unstructured":"Chen C, Dong Y, Liu F, et al. A study of antidepressant effect and mechanism on intranasal delivery of BDNF-HA2TAT\/AAV to rats with post-stroke depression. Neuropsychiatr Dis Treat. 2020;16:637\u201349. https:\/\/doi.org\/10.2147\/NDT.S227598.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"4417_CR81","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/jcp.30944","volume":"238","author":"JE Alvarez-Contino","year":"2023","unstructured":"Alvarez-Contino JE, D\u00edaz-S\u00e1nchez E, Mirchandani-Duque M, et al. GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions. J Cell Physiol. 2023;238(2):459\u201374. https:\/\/doi.org\/10.1002\/jcp.30944.","journal-title":"J Cell Physiol"},{"issue":"1","key":"4417_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00790","volume":"23","author":"Z Zang","year":"2026","unstructured":"Zang Z, Li A, Zhang Z, et al. Intranasal (R)-ketamine modulates depression symptom and neurotransmitters-associated human brain connectivity. Neurotherapeutics. 2026;23(1):e00790. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00790.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"4417_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2019.17.1.1","volume":"17","author":"F De Cagna","year":"2019","unstructured":"De Cagna F, Fusar-Poli L, Damiani S, et al. The role of intranasal oxytocin in anxiety and depressive disorders: a systematic review of randomized controlled trials. Clin Psychopharmacol Neurosci. 2019;17(1):1\u201311. https:\/\/doi.org\/10.9758\/cpn.2019.17.1.1.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"4417_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120751","volume":"395","author":"C Trenado","year":"2026","unstructured":"Trenado C, Seifritz E, Olbrich S, Ferrea S. The role of frontal EEG in predicting clinical response of major depressive disorder to intranasal ketamine and esketamine. J Affect Disord. 2026;395:120751. https:\/\/doi.org\/10.1016\/j.jad.2025.120751.","journal-title":"J Affect Disord"},{"issue":"2","key":"4417_CR85","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s12035-024-04375-2","volume":"62","author":"JM V\u00e1squez-P\u00e9rez","year":"2025","unstructured":"V\u00e1squez-P\u00e9rez JM, Gonz\u00e1lez-Guevara E, Guti\u00e9rrez-Buenabad D, Mart\u00ednez-Gopar PE, Martinez-Lazcano JC, C\u00e1rdenas G. Is Nasal Dysbiosis a Required Component for Neuroinflammation in Major Depressive Disorder? Mol Neurobiol. 2025;62(2):2459\u201369. https:\/\/doi.org\/10.1007\/s12035-024-04375-2.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"4417_CR86","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1038\/s41564-025-02120-6","volume":"10","author":"G Xiang","year":"2025","unstructured":"Xiang G, Wang Y, Ni K, et al. Nasal Staphylococcus aureus carriage promotes depressive behaviour in mice via sex hormone degradation. Nat Microbiol. 2025;10(10):2425\u201340. https:\/\/doi.org\/10.1038\/s41564-025-02120-6.","journal-title":"Nat Microbiol"},{"issue":"5","key":"4417_CR87","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.4088\/JCP.15f10026","volume":"76","author":"C Andrade","year":"2015","unstructured":"Andrade C. Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. J Clin Psychiatry. 2015;76(5):e628\u201331. https:\/\/doi.org\/10.4088\/JCP.15f10026.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"4417_CR88","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1124\/jpet.123.001824","volume":"388","author":"A Ribeiro-Davis","year":"2024","unstructured":"Ribeiro-Davis A, Al Saeedy DY, Jahr FM, Hawkins E, McClay JL, Deshpande LS. Ketamine Produces Antidepressant Effects by Inhibiting Histone Deacetylases and Upregulating Hippocampal Brain-Derived Neurotrophic Factor Levels in a Diisopropyl Fluorophosphate-Based Rat Model of Gulf War Illness. J Pharmacol Exp Ther. 2024;388(2):647\u201354. https:\/\/doi.org\/10.1124\/jpet.123.001824.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4417_CR89","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.18632\/aging.202358","volume":"13","author":"G Ren","year":"2021","unstructured":"Ren G, Xue P, Wu B, Yang F, Wu X. Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via CREB-mediated adult neurogenesis in mouse depression model. Aging. 2021;13(3):3898\u2013908. https:\/\/doi.org\/10.18632\/aging.202358.","journal-title":"Aging"},{"key":"4417_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1463976","volume":"11","author":"A Kisku","year":"2024","unstructured":"Kisku A, Nishad A, Agrawal S, et al. Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders. Front Med (Lausanne). 2024;11:1463976. https:\/\/doi.org\/10.3389\/fmed.2024.1463976.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"4417_CR91","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapsychiatry.2025.1317","volume":"82","author":"A Janik","year":"2025","unstructured":"Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(9):877\u201387. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1317.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"4417_CR92","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.25m15789","volume":"86","author":"R Meisner","year":"2025","unstructured":"Meisner R, Li S, Boyle B, et al. Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review. J Clin Psychiatry. 2025;86(4):25m15789. https:\/\/doi.org\/10.4088\/JCP.25m15789.","journal-title":"J Clin Psychiatry"},{"key":"4417_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109693","volume":"240","author":"M Ni","year":"2023","unstructured":"Ni M, Zheng M, Chen B, et al. Microglial stimulation triggered by intranasal lipopolysaccharide administration produces antidepressant-like effect through ERK1\/2-mediated BDNF synthesis in the hippocampus. Neuropharmacology. 2023;240:109693. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109693.","journal-title":"Neuropharmacology"},{"key":"4417_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2025.174114","volume":"257","author":"W Hu","year":"2025","unstructured":"Hu W, Ye M, Dai Q, et al. Intranasal LAG3 antibody infusion induces microglia-dependent antidepressant effect by mobilizing astrocytic P2Y1R-mediated BDNF synthesis in the hippocampus. Pharmacol Biochem Behav. 2025;257:174114. https:\/\/doi.org\/10.1016\/j.pbb.2025.174114.","journal-title":"Pharmacol Biochem Behav"},{"key":"4417_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1577331","volume":"16","author":"M Ma","year":"2025","unstructured":"Ma M, Ma R, Md G, et al. Escitalopram oxalate-loaded chitosan nanoparticle in situ gel formulation intended for direct nose-to-brain delivery: in vitro, ex vivo, and in vivo pharmacokinetic evaluation. Front Pharmacol. 2025;16:1577331. https:\/\/doi.org\/10.3389\/fphar.2025.1577331.","journal-title":"Front Pharmacol"},{"issue":"4","key":"4417_CR96","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5152\/alphapsychiatry.2024.241549","volume":"25","author":"F Bartoli","year":"2024","unstructured":"Bartoli F, Cavaleri D, Riboldi I, et al. The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol. Alpha Psychiatry. 2024;25(4):555\u201360. https:\/\/doi.org\/10.5152\/alphapsychiatry.2024.241549.","journal-title":"Alpha Psychiatry"},{"issue":"1","key":"4417_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04435-x","volume":"23","author":"F Naudet","year":"2025","unstructured":"Naudet F, Pellen C, Fodor LA, et al. Efficacy and safety of esketamine for \u201ctreatment resistant depression\u201d: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Med. 2025;23(1):677. https:\/\/doi.org\/10.1186\/s12916-025-04435-x.","journal-title":"BMC Med"},{"key":"4417_CR98","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euroneuro.2024.05.009","volume":"85","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Bitter I, Buyze J, et al. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. Eur Neuropsychopharmacol. 2024;85:58\u201365. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.05.009.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"4417_CR99","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14740338.2022.2058488","volume":"21","author":"MY Jawad","year":"2022","unstructured":"Jawad MY, Di Vincenzo JD, Ceban F, et al. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(6):841\u201352. https:\/\/doi.org\/10.1080\/14740338.2022.2058488.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"4417_CR100","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3):19m12891. https:\/\/doi.org\/10.4088\/JCP.19m12891.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"4417_CR101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14656566.2019.1683161","volume":"21","author":"J Kryst","year":"2020","unstructured":"Kryst J, Kawalec P, Pilc A. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2020;21(1):9\u201320. https:\/\/doi.org\/10.1080\/14656566.2019.1683161.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"4417_CR102","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","volume":"41","author":"CM Canuso","year":"2021","unstructured":"Canuso CM, Ionescu DF, Li X, Qiu X, Lane R, Turkoz I, et al. Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior. J Clin Psychopharmacol. 2021;41(5):516\u201324. https:\/\/doi.org\/10.1097\/JCP.0000000000001465.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4417_CR103","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13191","volume":"81","author":"DJ Fu","year":"2020","unstructured":"Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. https:\/\/doi.org\/10.4088\/JCP.19m13191.","journal-title":"J Clin Psychiatry"},{"key":"4417_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00262-x","volume":"19","author":"NA Bossaller","year":"2020","unstructured":"Bossaller NA, Shelton RC. Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report. Ann Gen Psychiatry. 2020;19:13. https:\/\/doi.org\/10.1186\/s12991-020-00262-x.","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"4417_CR105","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/YIC.0000000000000327","volume":"36","author":"S Pereira","year":"2021","unstructured":"Pereira S, Brennan E, Patel A, Moran M, Wallier J, Liebowitz MR. Managing dissociative symptoms following the use of esketamine nasal spray: a case report. Int Clin Psychopharmacol. 2021;36(1):54\u20137. https:\/\/doi.org\/10.1097\/YIC.0000000000000327.","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"4417_CR106","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae058","volume":"27","author":"C Chepke","year":"2024","unstructured":"Chepke C, Shelton R, Sanacora G, Doherty T, Tsytsik P, Parker N. Real-world safety of Esketamine nasal spray: a comprehensive analysis of Esketamine and respiratory depression. Int J Neuropsychopharmacol. 2024;27(12):pyae058. https:\/\/doi.org\/10.1093\/ijnp\/pyae058.","journal-title":"Int J Neuropsychopharmacol"},{"key":"4417_CR107","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2147\/NDT.S548944","volume":"21","author":"AA Raza","year":"2025","unstructured":"Raza AA, Ahmed GU, Zafar H, Akhtar SO, Bin Mobin M, Samadi A. Spravato for treatment-resistant depression: efficacy and sexual side effect profile. Neuropsychiatr Dis Treat. 2025;21:2125\u201340. https:\/\/doi.org\/10.2147\/NDT.S548944.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"4417_CR108","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40262-023-01273-z","volume":"62","author":"P Zannikos","year":"2023","unstructured":"Zannikos P, Solanki B, De Meulder M, Badorrek P, Hohlfeld JM, Singh J. Pharmacokinetics of nasal esketamine in patients with allergic rhinitis with and without nasal decongestant pretreatment and in healthy subjects with and without nasal corticosteroid pretreatment. Clin Pharmacokinet. 2023;62(9):1315\u201328. https:\/\/doi.org\/10.1007\/s40262-023-01273-z.","journal-title":"Clin Pharmacokinet"},{"key":"4417_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124866","volume":"667","author":"R Upadhyay","year":"2024","unstructured":"Upadhyay R, Ghosh P, Desavathu M. Advancement in the nose-to-brain drug delivery of FDA-approved drugs for the better management of depression and psychiatric disorders. Int J Pharm. 2024;667:124866. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124866.","journal-title":"Int J Pharm"},{"issue":"12","key":"4417_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122742","volume":"14","author":"M Alberto","year":"2022","unstructured":"Alberto M, Paiva-Santos AC, Veiga F, Pires PC. Lipid and polymeric nanoparticles: successful strategies for nose-to-brain drug delivery in the treatment of depression and anxiety disorders. Pharmaceutics. 2022;14(12):2742. https:\/\/doi.org\/10.3390\/pharmaceutics14122742.","journal-title":"Pharmaceutics"},{"issue":"10","key":"4417_CR111","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/17460441.2020.1776697","volume":"15","author":"M Panek","year":"2020","unstructured":"Panek M, Kawalec P, Pilc A, Laso\u0144 W. Developments in the discovery and design of intranasal antidepressants. Expert Opin Drug Discov. 2020;15(10):1145\u201364. https:\/\/doi.org\/10.1080\/17460441.2020.1776697.","journal-title":"Expert Opin Drug Discov"},{"issue":"9","key":"4417_CR112","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1017\/S0033291724000217","volume":"54","author":"MA Ellenbogen","year":"2024","unstructured":"Ellenbogen MA, Cardoso C, Serravalle L, Vadaga K, Joober R. The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial. Psychol Med. 2024;54(9):2122\u201332. https:\/\/doi.org\/10.1017\/S0033291724000217.","journal-title":"Psychol Med"},{"issue":"5","key":"4417_CR113","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s12325-025-03149-z","volume":"42","author":"P Molero","year":"2025","unstructured":"Molero P, Iba\u00f1ez A, de Diego-Ali\u00f1o J, Ramos-Quiroga JA, Garc\u00eda Dorado M, L\u00f3pez Rengel PM, et al. A real-world study on the use, effectiveness, and safety of esketamine nasal spray in patients with treatment-resistant depression: INTEGRATE study. Adv Ther. 2025;42(5):2335\u201353. https:\/\/doi.org\/10.1007\/s12325-025-03149-z.","journal-title":"Adv Ther"},{"key":"4417_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119756","volume":"389","author":"DKY Leung","year":"2025","unstructured":"Leung DKY, Wong DHS, Wong FHC, Wong SMY, Chan OLH, Wong GHY, et al. The effects of delivery format on the effectiveness and acceptability of self-guided interventions for depression in older adults: a systematic review and meta-analysis. J Affect Disord. 2025;389:119756. https:\/\/doi.org\/10.1016\/j.jad.2025.119756.","journal-title":"J Affect Disord"},{"issue":"2","key":"4417_CR115","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/PRA.0000000000000531","volume":"27","author":"SH Preskorn","year":"2021","unstructured":"Preskorn SH. Consistency of the antidepressant effect of intranasal esketamine in phase 3 clinical trials. J Psychiatr Pract. 2021;27(2):115\u201320. https:\/\/doi.org\/10.1097\/PRA.0000000000000531.","journal-title":"J Psychiatr Pract"},{"key":"4417_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1623659","volume":"16","author":"F Mora","year":"2025","unstructured":"Mora F, Ramos-Quiroga JA, Baca-Garc\u00eda E, et al. Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects. Front Psychiatry. 2025;16:1623659. https:\/\/doi.org\/10.3389\/fpsyt.2025.1623659.","journal-title":"Front Psychiatry"},{"issue":"1","key":"4417_CR117","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf080","volume":"29","author":"CR Conway","year":"2026","unstructured":"Conway CR, Rush AJ, Aaronson ST, et al. Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report. Int J Neuropsychopharmacol. 2026;29(1):pyaf080. https:\/\/doi.org\/10.1093\/ijnp\/pyaf080.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"4417_CR118","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/MJT.0000000000001721","volume":"31","author":"VD Evans","year":"2024","unstructured":"Evans VD, Arenas A, Shinozuka K, et al. Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine. Am J Ther. 2024;31(2):e155\u201377. https:\/\/doi.org\/10.1097\/MJT.0000000000001721.","journal-title":"Am J Ther"},{"issue":"6","key":"4417_CR119","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","volume":"21","author":"S Nikayin","year":"2022","unstructured":"Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf. 2022;21(6):777\u201387. https:\/\/doi.org\/10.1080\/14740338.2022.2066651.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"4417_CR120","doi-asserted-by":"publisher","first-page":"pyaf027","DOI":"10.1093\/ijnp\/pyaf027","volume":"28","author":"N Zaki","year":"2025","unstructured":"Zaki N, Chen LN, Lane R, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. 2025;28(6):pyaf027. https:\/\/doi.org\/10.1093\/ijnp\/pyaf027.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"4417_CR121","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14318","volume":"83","author":"DJ Williamson","year":"2022","unstructured":"Williamson DJ, Gogate JP, Kern Sliwa JK, et al. Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. J Clin Psychiatry. 2022;83(6):21m14318. https:\/\/doi.org\/10.4088\/JCP.21m14318.","journal-title":"J Clin Psychiatry"},{"key":"4417_CR122","doi-asserted-by":"publisher","unstructured":"Kern Sliwa J, Naranjo RR Jr, Turkoz I, Petrillo MP, Cabrera P, Trivedi M. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-\u00c5sberg Depression Rating Scale and the 9-item Patient Health Questionnaire. CNS Spectr. 2024;29(3):176\u201386. https:\/\/doi.org\/10.1017\/S1092852924000105.","DOI":"10.1017\/S1092852924000105"},{"key":"4417_CR123","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","volume":"276","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Carvalho IP, Lui LMW, et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. J Affect Disord. 2020;276:576\u201384. https:\/\/doi.org\/10.1016\/j.jad.2020.06.050.","journal-title":"J Affect Disord"},{"issue":"11","key":"4417_CR124","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s11136-023-03451-9","volume":"32","author":"C Jamieson","year":"2023","unstructured":"Jamieson C, Canuso CM, Ionescu DF, et al. Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II). Qual Life Res. 2023;32(11):3053\u201361. https:\/\/doi.org\/10.1007\/s11136-023-03451-9.","journal-title":"Qual Life Res"},{"issue":"1","key":"4417_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05017-y","volume":"23","author":"DJ Fu","year":"2023","unstructured":"Fu DJ, Zhang Q, Shi L, et al. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 2023;23(1):587. https:\/\/doi.org\/10.1186\/s12888-023-05017-y.","journal-title":"BMC Psychiatry"},{"issue":"10","key":"4417_CR126","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1176\/appi.ajp.20240655","volume":"182","author":"G Sanacora","year":"2025","unstructured":"Sanacora G, Ahmed M, Brown B, et al. Real-world safety of esketamine nasal spray: a comprehensive analysis almost 5 years after first approval. Am J Psychiatry. 2025;182(10):913\u201321. https:\/\/doi.org\/10.1176\/appi.ajp.20240655.","journal-title":"Am J Psychiatry"},{"key":"4417_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103609","volume":"90","author":"TS Kaster","year":"2025","unstructured":"Kaster TS, Dai Y, Vila-Rodriguez F, et al. Efficacy of intranasal esketamine versus rtms for treatment-resistant depression: analysis of individual participant data from two clinical trials. EClinicalMedicine. 2025;90:103609. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103609.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"4417_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02113-1","volume":"21","author":"C Jamieson","year":"2023","unstructured":"Jamieson C, Popova V, Daly E, et al. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Health Qual Life Outcomes. 2023;21(1):40. https:\/\/doi.org\/10.1186\/s12955-023-02113-1.","journal-title":"Health Qual Life Outcomes"},{"key":"4417_CR129","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241310685","volume":"16","author":"C Roncero","year":"2025","unstructured":"Roncero C, Merizalde-Torres M, Szerman N, et al. Is there a risk of esketamine misuse in clinical practice? Ther Adv Drug Saf. 2025;16:20420986241310685. https:\/\/doi.org\/10.1177\/20420986241310685.","journal-title":"Ther Adv Drug Saf"},{"key":"4417_CR130","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-025-09975-x","author":"B Anderson","year":"2025","unstructured":"Anderson B, O\u2019Grady M. An implementation science assessment of intranasal esketamine\u2019s limited integration into mainstream psychiatric treatment. J Behav Health Serv Res. 2025. https:\/\/doi.org\/10.1007\/s11414-025-09975-x.","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"4417_CR131","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/13696998.2023.2188845","volume":"26","author":"K Joshi","year":"2023","unstructured":"Joshi K, Pilon D, Shah A, Holiday C, Karkare S, Zhdanava M. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans. J Med Econ. 2023;26(1):422\u20139. https:\/\/doi.org\/10.1080\/13696998.2023.2188845.","journal-title":"J Med Econ"},{"issue":"2","key":"4417_CR132","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40801-024-00425-2","volume":"11","author":"L Harding","year":"2024","unstructured":"Harding L, Joshi K, Zhdanava M, et al. Treatment patterns, acute healthcare resource use, and costs of patients with treatment-resistant depression completing induction phase of esketamine in the United States. Drugs Real World Outcomes. 2024;11(2):209\u201319. https:\/\/doi.org\/10.1007\/s40801-024-00425-2.","journal-title":"Drugs Real World Outcomes"},{"issue":"7","key":"4417_CR133","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.5c00297","volume":"22","author":"S Rezaee","year":"2025","unstructured":"Rezaee S, Al-Majdoub ZM, Galetin A, Rostami-Hodjegan A, Ogungbenro K. Challenges and opportunities for incorporating physiological information into pharmacokinetic models of intranasal drug delivery to the brain: a review of the current status and future trajectories. Mol Pharm. 2025;22(7):3563\u201377. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00297.","journal-title":"Mol Pharm"},{"key":"4417_CR134","doi-asserted-by":"publisher","DOI":"10.54133\/ajms.v9i2.2460","author":"FJ Muna Yehia Ismail","year":"2025","unstructured":"Muna Yehia Ismail FJ, Al-Gawahri. Ex vivo and in vivo Assessment of Paliperidone Thermal in situ Gel as Nasal-to-Brain Delivery System in Rats. Al-Rafidain J Med Sci. 2025. https:\/\/doi.org\/10.54133\/ajms.v9i2.2460.","journal-title":"Al-Rafidain J Med Sci"},{"key":"4417_CR135","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/MDER.S70856","volume":"8","author":"T Kanazawa","year":"2015","unstructured":"Kanazawa T. Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. Med Devices (Auckl). 2015;8:57\u201364. https:\/\/doi.org\/10.2147\/MDER.S70856.","journal-title":"Med Devices (Auckl)"},{"issue":"4","key":"4417_CR136","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1248\/yakushi.17-00179","volume":"138","author":"T Kanazawa","year":"2018","unstructured":"Kanazawa T. Development of noninvasive drug delivery systems to the brain for the treatment of brain\/central nervous system diseases. Yakugaku Zasshi. 2018;138(4):443\u201350. https:\/\/doi.org\/10.1248\/yakushi.17-00179.","journal-title":"Yakugaku Zasshi"},{"issue":"1","key":"4417_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02005-y","volume":"21","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zhao M, Wang H, et al. Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression. J Nanobiotechnology. 2023;21(1):261. https:\/\/doi.org\/10.1186\/s12951-023-02005-y.","journal-title":"J Nanobiotechnology"},{"key":"4417_CR138","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jad.2025.04.059","volume":"382","author":"S Sun","year":"2025","unstructured":"Sun S, Rong J, Wang C, et al. Intranasal administration of exosomes derived from adipose mesenchymal stem cells ameliorates depressive-like behaviors and inhibits inflammation via AMPK\/mTOR-mediated autophagy. J Affect Disord. 2025;382:227\u201347. https:\/\/doi.org\/10.1016\/j.jad.2025.04.059.","journal-title":"J Affect Disord"},{"issue":"6","key":"4417_CR139","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4103\/1673-5374.385875","volume":"19","author":"S Gotoh","year":"2024","unstructured":"Gotoh S, Kawabori M, Fujimura M. Intranasal administration of stem cell-derived exosomes for central nervous system diseases. Neural Regen Res. 2024;19(6):1249\u201355. https:\/\/doi.org\/10.4103\/1673-5374.385875.","journal-title":"Neural Regen Res"},{"issue":"9","key":"4417_CR140","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1176\/appi.ajp.20240604","volume":"181","author":"TS Kaster","year":"2024","unstructured":"Kaster TS, Blumberger DM. Positioning rTMS within a sequential treatment algorithm of depression. Am J Psychiatry. 2024;181(9):781\u20133. https:\/\/doi.org\/10.1176\/appi.ajp.20240604.","journal-title":"Am J Psychiatry"},{"key":"4417_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1372650","volume":"15","author":"A Kupferberg","year":"2024","unstructured":"Kupferberg A, Hasler G. From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression. Front Psychiatry. 2024;15:1372650. https:\/\/doi.org\/10.3389\/fpsyt.2024.1372650.","journal-title":"Front Psychiatry"},{"issue":"1","key":"4417_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01642-z","volume":"20","author":"N Liu","year":"2022","unstructured":"Liu N, Yang C, Liang X, et al. Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain A\u03b2 burden and improves olfactory dysfunction of APP\/PS1 mice by nasal delivery. J Nanobiotechnol. 2022;20(1):439. https:\/\/doi.org\/10.1186\/s12951-022-01642-z.","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"4417_CR143","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40263-021-00826-9","volume":"35","author":"RL Doty","year":"2021","unstructured":"Doty RL, Popova V, Wylie C, et al. Effect of esketamine nasal spray on olfactory function and nasal tolerability in patients with treatment-resistant depression: results from four multicenter, randomized, double-blind, placebo-controlled, phase III studies. CNS Drugs. 2021;35(7):781\u201394. https:\/\/doi.org\/10.1007\/s40263-021-00826-9.","journal-title":"CNS Drugs"},{"issue":"1","key":"4417_CR144","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924002451","volume":"30","author":"RS McIntyre","year":"2025","unstructured":"McIntyre RS, Mattingly G, Godinov Y, et al. Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. CNS Spectr. 2025;30(1):e26. https:\/\/doi.org\/10.1017\/S1092852924002451.","journal-title":"CNS Spectr"},{"issue":"8","key":"4417_CR145","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1080\/03007995.2025.2555483","volume":"41","author":"K Clemens","year":"2025","unstructured":"Clemens K, Rive B, Joshi K, et al. Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression. Curr Med Res Opin. 2025;41(8):1549\u201357. https:\/\/doi.org\/10.1080\/03007995.2025.2555483.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"4417_CR146","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02917-4","volume":"25","author":"V Tanna","year":"2024","unstructured":"Tanna V, Vora A, Shah P, Nair AB, Shah J, Sawarkar SP. PLGA nanoparticles based mucoadhesive nasal in situ gel for enhanced brain delivery of topiramate. AAPS PharmSciTech. 2024;25(7):205. https:\/\/doi.org\/10.1208\/s12249-024-02917-4.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"4417_CR147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228463","volume":"15","author":"S Shim","year":"2020","unstructured":"Shim S, Soh SH, Im YB, et al. Induction of systemic immunity through nasal-associated lymphoid tissue (NALT) of mice intranasally immunized with Brucella abortus malate dehydrogenase-loaded chitosan nanoparticles. PLoS One. 2020;15(2):e0228463. https:\/\/doi.org\/10.1371\/journal.pone.0228463.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"4417_CR148","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0378-5173(95)04206-7","volume":"128","author":"L Pereswetoff-Morath","year":"1996","unstructured":"Pereswetoff-Morath L, Edman P. Immunological consequences of nasal drug delivery in dextran microspheres and ethyl(hydroxyethyl)cellulose in rats. Int J Pharm. 1996;128(1\u20132):23\u20138. https:\/\/doi.org\/10.1016\/0378-5173(95)04206-7.","journal-title":"Int J Pharm"},{"issue":"3","key":"4417_CR149","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s13346-025-02019-z","volume":"16","author":"E Morim","year":"2026","unstructured":"Morim E, Sarmento B, Pacheco C. Nanocarrier-based intranasal drug delivery for enhanced neurological disorders treatment. Drug Deliv Transl Res. 2026;16(3):761\u201379. https:\/\/doi.org\/10.1007\/s13346-025-02019-z.","journal-title":"Drug Deliv Transl Res"},{"key":"4417_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJN.S588836","volume":"21","author":"T Gao","year":"2026","unstructured":"Gao T, Chu Q, Xing X, Liu Y, Fu S, Liu D. Intranasal nano-delivery systems: emerging strategies for central nervous system disease therapeutics. Int J Nanomed. 2026;21:1\u201333. https:\/\/doi.org\/10.2147\/IJN.S588836.","journal-title":"Int J Nanomed"},{"issue":"8","key":"4417_CR151","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02946-z","volume":"25","author":"M Butola","year":"2024","unstructured":"Butola M, Nainwal N. Non-invasive techniques of nose to brain delivery using nanoparticulate carriers: hopes and hurdles. AAPS PharmSciTech. 2024;25(8):256. https:\/\/doi.org\/10.1208\/s12249-024-02946-z.","journal-title":"AAPS PharmSciTech"},{"key":"4417_CR152","doi-asserted-by":"publisher","first-page":"107313","DOI":"10.1016\/j.jddst.2025.107313","volume":"112","author":"NC Mina Mehanny","year":"2025","unstructured":"Mina Mehanny NC, Sabry H, Ihab Z, Ashraf M, Mostafa R, Hamed N, Wael F, Abdelkarim A, Younis A, Ismail L, Allam Y, Reda, Haidy E. Michel. Intranasal empagliflozin-loaded PLGA nanoparticles demonstrate neuroprotective effects against methotrexate-induced chemobrain in rats. J Drug Deliv Sci Technol. 2025;112:107313. https:\/\/doi.org\/10.1016\/j.jddst.2025.107313.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1\u20132","key":"4417_CR153","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0169-409x(97)00069-0","volume":"29","author":"L Pereswetoff-Morath","year":"1998","unstructured":"Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev. 1998;29(1\u20132):185\u201394. https:\/\/doi.org\/10.1016\/s0169-409x(97)00069-0.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"4417_CR154","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0378-5173(95)04205-9","volume":"128","author":"LP-MS Bjurstrom","year":"1996","unstructured":"Bjurstrom LP-MS, Khan R, Dahlin M, Edman P. Toxicological aspects of the use of dextran microspheres and thermogelling ethyl(hydroxyethyl) cellulose (EHEC) as nasal drug delivery systems. Int J Pharm. 1996;128(1\u20132):9\u201321. https:\/\/doi.org\/10.1016\/0378-5173(95)04205-9.","journal-title":"Int J Pharm"},{"key":"4417_CR155","doi-asserted-by":"publisher","DOI":"10.1002\/mame.202400356","volume":"310","author":"L Qian","year":"2025","unstructured":"Qian L, Cook MT, Dreiss CA. In situ gels for nasal delivery: formulation, characterization and applications. Macromol Mater Eng. 2025;310:2400356. https:\/\/doi.org\/10.1002\/mame.202400356.","journal-title":"Macromol Mater Eng"},{"issue":"22","key":"4417_CR156","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/pol.20230403","volume":"61","author":"J Singh","year":"2023","unstructured":"Singh J, Nayak P. <article-title update=\"added\"><scp>pH<\/scp>\u2010responsive polymers for drug delivery: trends and opportunities. J Polym Sci. 2023;61(22):2828. https:\/\/doi.org\/10.1002\/pol.20230403.","journal-title":"J. Polym. Sci."},{"issue":"1\u20132","key":"4417_CR157","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ijpharm.2014.07.025","volume":"473","author":"YM Gabal","year":"2014","unstructured":"Gabal YM, Kamel AO, Sammour OA, Elshafeey AH. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm. 2014;473(1\u20132):442\u201357. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.07.025.","journal-title":"Int J Pharm"},{"issue":"Part B","key":"4417_CR158","doi-asserted-by":"publisher","first-page":"106417","DOI":"10.1016\/j.jddst.2024.106417","volume":"102","author":"M Adel Alhowyan","year":"2024","unstructured":"Adel Alhowyan M, Imran A, Haque MA, Kalam. Surface-engineered Niosomes of Esculin Hydrate for the management of depression via intranasal route: Optimization, In vitro, Ex vivo and pharmacokinetic assessment. J Drug Deliv Sci Technol. 2024;102(Part B):106417. https:\/\/doi.org\/10.1016\/j.jddst.2024.106417.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4417_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120994","volume":"607","author":"F Laffleur","year":"2021","unstructured":"Laffleur F, Bauer B. Progress in nasal drug delivery systems. Int J Pharm. 2021;607:120994. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120994.","journal-title":"Int J Pharm"},{"key":"4417_CR160","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40263-022-00930-4","volume":"36","author":"A Lofts","year":"2022","unstructured":"Lofts A, Abu-Hijleh F, Rigg N, et al. Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: rationale, successes, and future needs. CNS Drugs. 2022;36:739\u201370. https:\/\/doi.org\/10.1007\/s40263-022-00930-4.","journal-title":"CNS Drugs"},{"issue":"10","key":"4417_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102070","volume":"14","author":"Z Jin","year":"2022","unstructured":"Jin Z, Han Y, Zhang D, et al. Application of intranasal administration in the delivery of antidepressant active ingredients. Pharmaceutics. 2022;14(10):2070. https:\/\/doi.org\/10.3390\/pharmaceutics14102070.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4417_CR162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr. 2018;75(2):139\u201348. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3739.","journal-title":"JAMA Psychiatr"},{"issue":"17","key":"4417_CR163","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/ajhp\/zxaa191","volume":"77","author":"F Khorassani","year":"2020","unstructured":"Khorassani F, Talreja O. Intranasal esketamine: a novel drug for treatment-resistant depression. Am J Health-Syst Pharm. 2020;77(17):1382\u20138. https:\/\/doi.org\/10.1093\/ajhp\/zxaa191.","journal-title":"Am J Health-Syst Pharm"},{"key":"4417_CR164","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/NDT.S391096","volume":"19","author":"X Chen","year":"2023","unstructured":"Chen X, Hou X, Bai D, et al. Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA. Neuropsychiatr Dis Treat. 2023;19:693\u2013707. https:\/\/doi.org\/10.2147\/NDT.S391096.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4417_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119776","volume":"589","author":"A-T Chatzitaki","year":"2020","unstructured":"Chatzitaki A-T, Jesus S, Karavasili C, Andreadis D, Fatouros DG, Borges O. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. Int J Pharm. 2020;589:119776. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119776.","journal-title":"Int J Pharm"},{"issue":"3","key":"4417_CR166","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1039\/d4nr04250f","volume":"17","author":"S Sharma","year":"2025","unstructured":"Sharma S, Gauba P, Tyagi A, Dang S. Chitosan-modified polymeric nanoparticles for the nose-to-brain drug delivery of paroxetine: an in vitro and in vivo evaluation. Nanoscale. 2025;17(3):1687\u2013702. https:\/\/doi.org\/10.1039\/d4nr04250f.","journal-title":"Nanoscale"},{"issue":"17","key":"4417_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/nano15171361","volume":"15","author":"A Baroni","year":"2025","unstructured":"Baroni A, Moulton C, Cristina M, Sansone L, Belli M, Tasciotti E. Nano- and microplastics in the brain: an emerging threat to neural health. Nanomaterials. 2025;15(17):1361. https:\/\/doi.org\/10.3390\/nano15171361.","journal-title":"Nanomaterials"},{"issue":"8","key":"4417_CR168","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1166\/jnn.2009.gr02","volume":"9","author":"G Oberd\u00f6rster","year":"2009","unstructured":"Oberd\u00f6rster G, Elder A, Rinderknecht A. Nanoparticles and the brain: cause for concern? J Nanosci Nanotechnol. 2009;9(8):4996\u20135007. https:\/\/doi.org\/10.1166\/jnn.2009.gr02.","journal-title":"J Nanosci Nanotechnol"},{"key":"4417_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2024.142380","volume":"361","author":"A Kaushik","year":"2024","unstructured":"Kaushik A, Singh A, Kumar Gupta V, Mishra YK. Nano\/micro-plastic, an invisible threat getting into the brain. Chemosphere. 2024;361:142380. https:\/\/doi.org\/10.1016\/j.chemosphere.2024.142380.","journal-title":"Chemosphere"},{"issue":"1","key":"4417_CR170","doi-asserted-by":"publisher","DOI":"10.1007\/s42114-025-01227-y","volume":"8","author":"M Yuan","year":"2025","unstructured":"Yuan M, Han Z, Somayaji Y, et al. Intranasal delivery of metformin using metal-organic framework (MOF)-74-Mg nanocarriers. Adv Compos Hybrid Mater. 2025;8(1):131. https:\/\/doi.org\/10.1007\/s42114-025-01227-y.","journal-title":"Adv Compos Hybrid Mater"},{"key":"4417_CR171","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbi.2016.09.015","volume":"60","author":"M Denizet","year":"2017","unstructured":"Denizet M, Cotter L, Lledo PM, Lazarini F. Sensory deprivation increases phagocytosis of adult-born neurons by activated microglia in the olfactory bulb. Brain Behav Immun. 2017;60:38\u201343. https:\/\/doi.org\/10.1016\/j.bbi.2016.09.015.","journal-title":"Brain Behav Immun"},{"issue":"2","key":"4417_CR172","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1023\/a:1011922819926","volume":"15","author":"M Tob\u00edo","year":"1998","unstructured":"Tob\u00edo M, Gref R, S\u00e1nchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res. 1998;15(2):270\u20135. https:\/\/doi.org\/10.1023\/a:1011922819926.","journal-title":"Pharm Res"},{"key":"4417_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105564","volume":"95","author":"S Alghareeb","year":"2024","unstructured":"Alghareeb S, Asare-Addo K, Conway BR, Adebisi AO. PLGA nanoparticles for nasal drug delivery. J Drug Deliv Sci Technol. 2024;95:105564. https:\/\/doi.org\/10.1016\/j.jddst.2024.105564.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4417_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.131491","volume":"267","author":"DG Gadhave","year":"2024","unstructured":"Gadhave DG, Quadros M, Ugale AR, Goyal M, Ayehunie S, Gupta V. Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine \u2013 development & characterization in physiologically relevant 3D tissue models. Int J Biol Macromol. 2024;267:131491. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.131491.","journal-title":"Int J Biol Macromol"},{"key":"4417_CR175","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","volume":"67","author":"S Bhavna, Md","year":"2014","unstructured":"Bhavna, Md S, Ali M, et al. Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int J Biol Macromol. 2014;67:418\u201325. https:\/\/doi.org\/10.1016\/j.ijbiomac.2014.03.022.","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"4417_CR176","doi-asserted-by":"publisher","first-page":"e41495","DOI":"10.1097\/MD.0000000000041495","volume":"104","author":"Ouyang","year":"2025","unstructured":"Ouyang, Yannan. Li Juan.Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. Medicine. 2025;104(9):e41495. https:\/\/doi.org\/10.1097\/MD.0000000000041495.","journal-title":"Medicine"},{"key":"4417_CR177","doi-asserted-by":"publisher","unstructured":"Bhaskara Gowthami I, Mehta S, Baiju A, Appani T, Suvarna. Kiratjyot Singh Randhawa, Anuj Manish Kakkad, Afzal Biabani Syed, Vaishnavi Kumar, Harshawardhan Dhanraj Ramteke, Rakhshanda khan. Efficacy and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. preprint arXiv 2025. https:\/\/doi.org\/10.1101\/2025.09.22.25336317","DOI":"10.1101\/2025.09.22.25336317"},{"issue":"36","key":"4417_CR178","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039484","volume":"103","author":"Y Chen","year":"2024","unstructured":"Chen Y, Gu H, Li W, Chen Y. A real-world pharmacovigilance study of esketamine nasal spray. Medicine (Baltimore). 2024;103(36):e39484. https:\/\/doi.org\/10.1097\/MD.0000000000039484.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4417_CR179","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/j3nc79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, Fortuna A, Alves G, Falc\u00e3o A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288\u2013311. https:\/\/doi.org\/10.18433\/j3nc79.","journal-title":"J Pharm Pharm Sci"},{"issue":"7","key":"4417_CR180","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614\u201328. https:\/\/doi.org\/10.1016\/j.addr.2011.11.002.","journal-title":"Adv Drug Deliv Rev"},{"key":"4417_CR181","doi-asserted-by":"publisher","unstructured":"Durgun ME, \u00c7aml\u0131k G, De\u011fim \u0130T, \u00d6zsoy Y. Nose-to-Brain Delivery of Peptides and Proteins. In: Pathak YV, Yadav HKS, editors. Nasal Drug Delivery. Cham: Springer; 2023. https:\/\/doi.org\/10.1007\/978-3-031-23112-4_10.","DOI":"10.1007\/978-3-031-23112-4_10"},{"issue":"4","key":"4417_CR182","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","volume":"6","author":"H Gao","year":"2016","unstructured":"Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6(4):268\u201386. https:\/\/doi.org\/10.1016\/j.apsb.2016.05.013.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4417_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10010034","volume":"10","author":"F Sonvico","year":"2018","unstructured":"Sonvico F, Clementino A, Buttini F, et al. Surface-modified nanocarriers for nose-to-brain delivery: From bioadhesion to targeting. Pharmaceutics. 2018;10(1):34. https:\/\/doi.org\/10.3390\/pharmaceutics10010034.","journal-title":"Pharmaceutics"},{"key":"4417_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2026.100521","volume":"11","author":"B Alwali","year":"2026","unstructured":"Alwali B, Parumasivam T, Al-Tabakha MM. Intranasal drug delivery: unlocking the nose-to-brain route for central nervous system therapies. Int J Pharm. 2026;100521. https:\/\/doi.org\/10.1016\/j.ijpx.2026.100521.","journal-title":"Int J Pharm"},{"issue":"9","key":"4417_CR185","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","volume":"27","author":"GC Medeiros","year":"2022","unstructured":"Medeiros GC, Gould TD, Prueitt WL, et al. Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis. Mol Psychiatry. 2022;27(9):3658\u201369. https:\/\/doi.org\/10.1038\/s41380-022-01652-1.","journal-title":"Mol Psychiatry"},{"key":"4417_CR186","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2147\/NDT.S486118","volume":"20","author":"H Song","year":"2024","unstructured":"Song H, Luo Y, Fang L. Esketamine nasal spray: rapid relief for TRD and suicide prevention-mechanisms and pharmacodynamics. Neuropsychiatr Dis Treat. 2024;20:2059\u201371. https:\/\/doi.org\/10.2147\/NDT.S486118.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"4417_CR187","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1176\/appi.ps.201900625","volume":"71","author":"EL Ross","year":"2020","unstructured":"Ross EL, Soeteman DI. Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatr Serv. 2020;71(10):988\u201397. https:\/\/doi.org\/10.1176\/appi.ps.201900625.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"4417_CR188","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.36","volume":"9","author":"DM Dietch","year":"2023","unstructured":"Dietch DM, Kerr-Gaffney J, Hockey M, et al. Efficacy of low carbohydrate and ketogenic diets in treating mood and anxiety disorders: systematic review and implications for clinical practice. BJPsych Open. 2023;9(3):e70. https:\/\/doi.org\/10.1192\/bjo.2023.36.","journal-title":"BJPsych Open"},{"key":"4417_CR189","unstructured":"US Food and Drug Administration. Guidance for industry: reformulated drug products\u2014comparability assessment. 2023."},{"key":"4417_CR190","unstructured":"European Medicines Agency. Reflection paper on reformulations of centrally authorised medicinal products. 2022."},{"key":"4417_CR191","doi-asserted-by":"publisher","unstructured":"Onzi G, Guterres SS, Pohlmann AR, Frank LA. Stimuli-Responsive Nanocarriers for Drug Delivery. In: The ADME Encyclopedia. Cham: Springer; 2021. https:\/\/doi.org\/10.1007\/978-3-030-51519-5_177-1.","DOI":"10.1007\/978-3-030-51519-5_177-1"},{"issue":"1","key":"4417_CR192","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/ejn.14630","volume":"53","author":"RS Duman","year":"2021","unstructured":"Duman RS, Deyama S, Foga\u00e7a MV. Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants. Eur J Neurosci. 2021;53(1):126\u201339. https:\/\/doi.org\/10.1111\/ejn.14630.","journal-title":"Eur J Neurosci"},{"issue":"9","key":"4417_CR193","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189.","journal-title":"JAMA Psychiatry"},{"key":"4417_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102915","volume":"78","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine. 2024;78:102915. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102915.","journal-title":"EClinicalMedicine"},{"key":"4417_CR195","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jad.2022.09.083","volume":"319","author":"M Brendle","year":"2022","unstructured":"Brendle M, Robison R, Malone DC. Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. J Affect Disord. 2022;319:388\u201396. https:\/\/doi.org\/10.1016\/j.jad.2022.09.083.","journal-title":"J Affect Disord"},{"issue":"5","key":"4417_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/genes14051095","volume":"14","author":"M Radosavljevic","year":"2023","unstructured":"Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes Basel. 2023;14(5):1095. https:\/\/doi.org\/10.3390\/genes14051095.","journal-title":"Genes Basel"},{"issue":"5","key":"4417_CR197","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2215-0366(15)00579-9","volume":"3","author":"LM Williams","year":"2016","unstructured":"Williams LM. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016;3(5):472\u201380. https:\/\/doi.org\/10.1016\/S2215-0366(15)00579-9.","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"4417_CR198","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17352","volume":"13","author":"A Sapkota","year":"2021","unstructured":"Sapkota A, Khurshid H, Qureshi IA, et al. Efficacy and safety of intranasal esketamine in treatment-resistant depression in adults: a systematic review. Cureus. 2021;13(8):e17352. https:\/\/doi.org\/10.7759\/cureus.17352.","journal-title":"Cureus"},{"issue":"9","key":"4417_CR199","doi-asserted-by":"publisher","first-page":"e91829","DOI":"10.7759\/cureus.91829","volume":"17","author":"SS Bhavya","year":"2025","unstructured":"Bhavya SS, Sadasivam B. A New Era for Esketamine in Managing Treatment-Resistant Depression: A Systematic Review of Its Use From Adjunct to First-Line Therapy. Cureus. 2025;17(9):e91829. https:\/\/doi.org\/10.7759\/cureus.91829.","journal-title":"Cureus"},{"issue":"7","key":"4417_CR200","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/17425247.2013.790887","volume":"10","author":"CV Pardeshi","year":"2013","unstructured":"Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013;10(7):957\u201372. https:\/\/doi.org\/10.1517\/17425247.2013.790887.","journal-title":"Expert Opin Drug Deliv"},{"issue":"6103","key":"4417_CR201","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68\u201372. https:\/\/doi.org\/10.1126\/science.1222939.","journal-title":"Science"},{"issue":"1","key":"4417_CR202","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1155\/2013\/984845","volume":"35","author":"C Labermaier","year":"2013","unstructured":"Labermaier C, Masana M, M\u00fcller MB. Biomarkers predicting antidepressant treatment response: how can we advance the field? Dis Markers. 2013;35(1):23\u201331. https:\/\/doi.org\/10.1155\/2013\/984845.","journal-title":"Dis Markers"},{"issue":"6","key":"4417_CR203","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449\u201359. https:\/\/doi.org\/10.1007\/s11920-007-0061-3.","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"4417_CR204","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2215-0366(24)00092-0","volume":"11","author":"C Sartor","year":"2024","unstructured":"Sartor C, Hussian M. Mental health implementation science: integrating lived experience expertise. Lancet Psychiatry. 2024;11(5):321\u20132. https:\/\/doi.org\/10.1016\/S2215-0366(24)00092-0.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"4417_CR205","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2025.10950","volume":"12","author":"N Ayad","year":"2026","unstructured":"Ayad N, Abdel Aziz K, Makhoul S, Abbas B, Javaid SF. Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions. BJPsych Open. 2026;12(1):e48. https:\/\/doi.org\/10.1192\/bjo.2025.10950.","journal-title":"BJPsych Open"},{"issue":"6","key":"4417_CR206","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/a-2590-3469","volume":"58","author":"LC Dormegny-Jeanjean","year":"2025","unstructured":"Dormegny-Jeanjean LC, Lenoir S, Humbert I, et al. Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses. Pharmacopsychiatry. 2025;58(6):273\u201383. https:\/\/doi.org\/10.1055\/a-2590-3469.","journal-title":"Pharmacopsychiatry"},{"key":"4417_CR207","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jad.2020.01.002","volume":"265","author":"W Zheng","year":"2020","unstructured":"Zheng W, Cai DB, Xiang YQ, et al. Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63\u201370. https:\/\/doi.org\/10.1016\/j.jad.2020.01.002.","journal-title":"J Affect Disord"},{"issue":"6","key":"4417_CR208","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428\u201338. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"4417_CR209","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1016\/j.xphs.2024.08.026","volume":"113","author":"OA Alsaidan","year":"2024","unstructured":"Alsaidan OA, Elkomy MH, Zaki RM, Tulbah AS, Yusif RM, Eid HM. Brain targeting of venlafaxine via intranasal transbilosomes thermogel for improved management of depressive disorder. J Pharm Sci. 2024;113(11):3304\u201314. https:\/\/doi.org\/10.1016\/j.xphs.2024.08.026.","journal-title":"J Pharm Sci"},{"key":"4417_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2025.114909","volume":"217","author":"S Elsalhy","year":"2025","unstructured":"Elsalhy S, Refai H, Osman DA, Sayed NE, Khalifa MKA. Optimization of intranasal trifluoperazine\/SPION-leciplex thermosensitive organogel for depression therapy: Pharmacodynamic and pharmacokinetic comparison of magnet placement effects on brain versus nose. Eur J Pharm Biopharm. 2025;217:114909. https:\/\/doi.org\/10.1016\/j.ejpb.2025.114909.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"4417_CR211","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/13651501.2022.2030757","volume":"26","author":"L Samalin","year":"2022","unstructured":"Samalin L, Roth\u00e4rmel M, Mekaoui L, et al. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. Int J Psychiatry Clin Pract. 2022;26(4):352\u201362. https:\/\/doi.org\/10.1080\/13651501.2022.2030757.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"18","key":"4417_CR212","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/cer-2022-0149","volume":"11","author":"M Brendle","year":"2022","unstructured":"Brendle M, Ahuja S, Valle MD, et al. Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. J Comp Eff Res. 2022;11(18):1323\u201336. https:\/\/doi.org\/10.2217\/cer-2022-0149.","journal-title":"J Comp Eff Res"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04417-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:18:54Z","timestamp":1779668334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":212,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4417"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04417-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"463"}}